GAO says FDA's foreign drug inspections can be improved
In testimony before a House subcommittee, the Government Accountability Office identifies weaknesses in the Food & Drug Administration's foreign drug inspection program.
Alarmed by the recent heparin contamination originating from China, the House Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, held a hearing yesterday on how the Food & Drug Administration can ensure drug safety. At the hearing, the Government Accountability Office
Recent Videos
Related Content
Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear
Brian Nowosielski;Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP;Ashley Gallagher
January 13th 2025Article
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.
